by Co-Diagnostics | Nov 15, 2017 | News Release
SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced corporate developments and financial results for the third quarter of 2017,...
by Co-Diagnostics | Nov 7, 2017 | News Release
SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, and Synbiotics Limited (“Synbiotics”), a group company of Asence Inc, a U.S....
by Co-Diagnostics | Nov 2, 2017 | News Release
SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, has been granted ISO 13485:2016 certification following successful completion of an audit...
